Copenhagen, Denmark – After five years of receiving infliximab (IFX) anti-TNF therapy, 61.8% of patients with ankylosing spondylitis (AS) showed substantial clinical benefit (ASAS40, ASsessment in AS, 40-response) and 27.6% achieved ASAS partial remission. Moreover, at five years, 78.4% of AS patients had no arthritis and 84.9% had no enthesitis...
Latest News
POTOMAC, Md. — IGC Pharma, Inc. provides details on its drug candidate TGR-63, which targets amyloid-beta plaque and can potentially improve Alzheimer’s disease treatment in a significant manner. A key pathological marker of Alzheimer’s disease is the formation of abnormal clusters of protein fragments called amyloid-beta (Aβ) that deposit as...
Barcelona, Spain – Researchers from the Germans Trias i Pujol Research Institute (IGTP) have made progress in exploring potential treatments for skin tumours associated with neurofibromatosis type 1. Their findings in cell models have been published in the journal JCI Insight. Neurofibromatosis type 1 is a rare genetic disorder that...
Stockholm, Sweden — Members of the AD-RIDDLE consortium announced today that they will begin a new initiative that aims to bridge the gap between Alzheimer’s research, implementation science, and precision medicine. The AD-RIDDLE programme will offer healthcare professionals a suite of validated solutions for timely detection and diagnosis of Alzheimer’s...
Bengaluru, India – The spread of tumour from the primary cancer site to distant organs, called metastasis, has puzzled scientists for many years – they are only now beginning to pinpoint triggers and mechanisms that drive this process. A new study from the Indian Institute of Science (IISc) shows how...
PARIS & LEIDEN, the Netherlands – Iktos, a company specialized in Artificial Intelligence for new drug design, and Facio Therapies, a drug discovery and development company focused on developing treatments for facioscapulohumeral dystrophy (FSHD), today announced entering a collaboration to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of...
DORVAL, QC – Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris® (canakinumab) for the treatment of active Still’s disease, including adult-onset Still’s disease (AOSD)[1]. AOSD is a rare form of inflammatory arthritis that can be a complex disease with variable presentation and potentially life-threatening complications[2]....
The midfielder is auctioning off his signed match-worn shirt from Manchester City’s 2-1 win over Borussia Dortmund in the first leg of our Champions League quarter-final, with all proceeds being used to help fund Dilara Abanoglu’s life-saving surgery. Dilara was diagnosed with Ollier’s Disease – a skeletal disorder which affects...
San Diego — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, begins a monthlong celebration of its 25th anniversary. A quarter-century after its founding in San Diego in April 1998, the company is commemorating its anniversary by celebrating its employees, customers, and entire stakeholder ecosystem,...
Birmingham, UK – Pathological abnormalities associated with motor neurone disease have been identified using a new technique developed at the University of Birmingham. The method will help scientists better understand the changes in the brain that lead to motor neurone disease (MND) and could eventually yield insights that will help...